1. Background {#sec186489}
=============

Nonalcoholic fatty liver disease (NAFLD) is the most common and prevalent liver disease worldwide ([@A37388R1]), the prevalence of the global has reached 25.24% (22.10 - 28.65) ([@A37388R2]). Accumulated evidence suggests that coronary artery disease (CAD) is closely related to the severity and progression of NAFLD, and it is the leading cause of mortality in NAFLD ([@A37388R3]). Adams et al. ([@A37388R4]) showed that cardiovascular disease accounted for about 25% of deaths in patients with NAFLD versus 13% of deaths in those with other liver diseases. Adiponectin (Ad), a 30-kDa peptide hormone, is almost exclusively secreted by adipose tissue ([@A37388R5]). The human Ad gene is located on chromosome 3q27, containing three exons and two introns and encoding 244 amino acids (6). Recently, several single-nucleotide polymorphisms of the Ad gene, such as *rs266729* (C \> G) and *rs2241766* (T \> G), were shown to be significantly associated with ([@A37388R6]). As one of the most abundant fat-derived biologically active proteins ([@A37388R7], [@A37388R8]), Ad plays an important role in the regulation of lipid metabolism and glucose metabolism, especially in improving insulin sensitivity, which is a key factor in the pathogenesis of NAFLD. Previous studies revealed a strong association between the presence of Ad polymorphisms and the risk of developing NAFLD, especially in patients of Chinese origin ([@A37388R9]-[@A37388R16]). The role of Ad polymorphisms in the susceptibility to CAD has been widely studied, but the results are inconsistent ([@A37388R17]-[@A37388R19]). Considering the high prevalence of CAD-related mortality in NAFLD patients ([@A37388R3]), identifying the potential association between Ad polymorphisms and the relative risk of developing CAD in NAFLD patients is extremely important.

2. Objectives {#sec186490}
=============

In the present study, we selected and genotyped two Ad gene polymorphisms, *rs266729* (C \> G) and *rs2241766* (T \> G), in NAFLD patients, with or without CAD and in healthy controls. We then investigated the association of these two Ad polymorphisms with the risk of developing CAD among NAFLD patients in a Chinese Han population.

3. Materials and Methods {#sec186495}
========================

3.1. Study Subjects {#sec186491}
-------------------

This case-control study was approved by the ethics committee on human research of Qingdao municipal hospital (Qingdao, China). Written informed consent was obtained from each subject prior to starting the study, and all the subjects in the study were of Northern Han Chinese origin. This study was performed in accordance with the principles of the declaration of Helsinki and its appendices ([@A37388R20]).

From April 2010 to May 2015, we selected 493 unrelated adult Chinese patients of both genders who had been diagnosed with NAFLD using B-type ultrasonography. Of those, 246 had CAD (127 males, 118 females, mean age of 61.54 ± 10.28 years), and 247 did not have CAD (126 males, 120 females, mean age of 62.13 ± 9.74 years). We also selected 304 healthy sex- and age-matched controls (152 males, 152 females, mean age of 61.31 ± 9.40 years). Data on the patients and healthy controls were collected from the department of gastroenterology and cardiology of Qingdao municipal hospital. NAFLD was diagnosed by a standard clinical evaluation, according to the criteria of the AASID ([@A37388R21]). The diagnosis of CAD was based on a percutaneous coronary angiogram, which was evaluated by two experienced interventional cardiologists. CAD was defined as the presence of at least 50% stenosis in at least one of the coronary arteries. The control volunteers were confirmed as being healthy by echocardiography, medical history, and general and laboratory examinations at the same hospital. Subjects who had cardiac disorders, other liver diseases, infectious disease, diabetes mellitus, concurrent major renal disease, or a history of medication were excluded.

3.2. Baseline Demographic and Biochemical Analyses {#sec186492}
--------------------------------------------------

We used a standard study questionnaire to obtain basic clinicopathological information (name, age, gender, height, weight, smoker, hypertension). The body mass index (BMI) was calculated using the following equation: BMI = weight/height^2^ (kg/m^2^) ([@A37388R22]).

After a 12-hour overnight fast, blood samples were collected from each subject in ethylene diamine tetraacetic acid-containing tubes. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), fasting plasma glucose (FPG), high-density lipoprotein (HDL) ,and low-density lipoprotein (LDL) were measured using routine enzymatic methods ([@A37388R23]). The concentration of total Ad was obtained by a radioimmunoassay, using a human Ad RIA kit.

3.3. Genomic DNA Extraction and Genotyping {#sec186493}
------------------------------------------

Genomic DNA was extracted using a genomic DNA purification kit (Beijing Bioteke biotechnology, Beijing, China) for peripheral blood, according to the manufacturer's instructions and stored at -20°C until use. The primers for PCR amplification of the fragments containing *rs266729* and *rs2241766* were synthesized by Shanghai Sangon Biotech company: Ad 5\'-CAGACACTTGCCCTGCCTCTGT-3\' and 5\'-TGGCAACATTCAACACCTTGGA-3\' for *rs266729*; 5\'-ACATGTGGATTCCAGGGCTCAG-3\' and 5\'-CTTCTCACCAGGGGTGCCATCT-3\' for *rs2241766*. The PCR amplification profile was as follows: predenaturation at 94°C for 5 minutes, 35 cycles, denaturation at 94°C for 20 seconds, annealing at 62°C for 30 seconds, extending at 72°C for 30 seconds, and finally extending at 72°C for 5 minutes to terminate the reaction. Target amplified fragments were then detected by gel electrophoresis in 2% gel with a 197-base and 218-base pair product, respectively. The Ad genotypes were detected by direct DNA sequencing using the ABI Prism sequence detection system ABI3730 (Foster City, CA, USA).

3.4. Statistical Analysis {#sec186494}
-------------------------

Differences in characteristics of the different groups were analyzed using the Student's t test or the χ^2^ test. Baseline characteristics are expressed as the mean ± standard deviation (S.D.), and categorical data are presented as percentages and numbers. The quantitative variables were distributed normally. Genotype and allele frequencies were assessed by counting the DNA sequencing data of each subject. Differences in the distributions of the patients versus those of the controls were analyzed by Pearson's χ^2^ test or Fisher's exact test, where appropriate. The Hardy-Weinberg equilibrium between expected and observed genotype distributions was estimated using the χ^2^ test. Logistic regression analysis was used to evaluate the association between the polymorphisms and presence/absence of CAD. The association was also determined by estimating the odds ratios (ORs), with their 95% confidence intervals (CIs). These statistical analyses were performed using SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA). All P values of less than 0.05 were considered statistically significant.

4. Results {#sec186499}
==========

4.1. Characteristics of the Study Participants {#sec186496}
----------------------------------------------

The baseline characteristics of the three groups (NAFLD with CAD, NAFLD without CAD, and healthy controls) according to the experimental requirements are shown in [Table 1](#tbl47200){ref-type="table"}. There were no significant age, gender, or height differences between the three groups (P \> 0.05). The prevalence of the weight, increased BMI, hypertension, serum ALT and AST levels, serum TG, TC, and LDL levels, FPG, decreased HDL and Ad levels in NAFLD subjects (with and without CAD) were significantly higher than in the controls (P \< 0.05).

###### Baseline Characteristics of the Study Participants^[a](#fn51931){ref-type="table-fn"}^

  Characteristics             Groups          P Value                                              
  --------------------------- --------------- --------------- -------------- ---------- ---------- ----------
  **Age, y**                  61.54 ± 10.28   62.13 ± 9.74    61.31 ± 9.40   0.514      0.782      0.316
  **Gender, Female/Male**     119/127         121/126         152/152        0.991      0.491      0.518
  **Height, m**               1.68 ± 0.07     1.68 ± 0.03     1.67 ± 0.08    1.032      1.342      0.782
  **Weight, kg**              67.46 ± 7.31    67.32 ± 7.42    66.54 ± 6.41   0.602      0.007      0.003
  **Smoker, No. (%)**         115 (46.7)      90 (36.4)       100 (32.9)     0.02       0.001      0.384
  **BMI, Kg/m** ^**2**^       25.83 ± 3.20    26.05 ± 3.36    23.13 ± 2.96   0.457      \< 0.001   \<0.001
  **Hypertension, No. (%)**   125 (50.8)      99 (40.1)       68 (22.4)      0.017      \< 0.001   \< 0.001
  **ALT, U/L**                41.88 ± 23.80   42.09 ± 23.12   20.75 ± 9.63   0.92       \< 0.001   \< 0.001
  **AST, U/L**                40.57 ± 22.01   41.49 ± 22.39   20.33 ± 8.13   0.647      \< 0.001   \< 0.001
  **TG, mmol/L**              2.34 ± 0.99     1.88 ± 0.81     1.35 ± 0.58    \< 0.001   \< 0.001   \< 0.001
  **TC, mmol/L**              5.22 ± 0.96     5.05 ± 0.94     4.32 ± 0.93    0.057      \< 0.001   \< 0.001
  **FPG, mmol/L**             5.32 ± 0.83     5.07 ± 0.53     4.93 ± 0.49    0.624      \< 0.001   \< 0.001
  **HDL, mmol/L**             1.21 ± 0.38     1.36 ± 0.41     1.56 ± 0.42    \< 0.001   \< 0.001   \< 0.001
  **LDL, mmol/L**             2.90 ± 0.86     2.70 ± 0.86     2.61 ± 0.75    0.011      \< 0.001   0.021
  **Adiponectin, ug/mL**      12.63 ± 2.83    15.31 ± 3.72    19.32 ± 3.21   \< 0.001   \< 0.001   \< 0.001

Abbreviations: CAD+NAFLD, nonalcoholic fatty liver disease patients with coronary artery disease; CAD-NAFLD, NALFD patients without CAD; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglycerides; TC, total cholesterol; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein; P1, CAD+NAFLD vs. CAD-NAFLD; P2, CAD+NAFLD vs. control; P3, CAD-NAFLD vs. control.

^a^Values are expressed as mean ± SD unless otherwise indicated.

Importantly, NAFLD patients with CAD had a higher prevalence of smoking and hypertension, increased weight, BMI, ALT, AST, TG, TC, FPG, and LDL, decreased HDL levels and Ad levels compared to the healthy controls (all P \< 0.05). In the NAFLD patients without CAD, we found an increased prevalence of smoking and hypertension, higher TG and LDL levels, and lower HDL and Ad levels compared to those with CAD (all P \< 0.05).

4.2. Ad rs266729 and rs2241766 Genotype and Allele Distribution {#sec186497}
---------------------------------------------------------------

The genotype distributions of *Ad rs266729* and *rs2241766* were correlated with the Hardy-Weinberg equilibrium in both the patients and controls (all P \> 0.05) ([Table 2](#tbl47201){ref-type="table"}). As shown in [Table 3](#tbl47202){ref-type="table"}, there was a significant difference in the genotypic and allelic distributions of the NAFLD patients and their control counterparts (OR: 0.414, 95% CI: 0.291 - 0.590, P \< 0.001; OR: 0.610, 95% CI: 0427 - 0.873, P = 0.007; OR: 0.473, 95% CI: 0.353 - 0.633, P \< 0.001, OR: 0.633, 95% CI: 0.468 - 0.855, P = 0.003, respectively) at position *Ad rs266729*. Moreover, there was a statistically significant difference at position *Ad rs266729* between the NAFLD patients with CAD versus those without CAD (OR: 0.679, 95% CI: 0.474 - 0.970, P = 0.033; OR: 0.747, 95% CI: 0.561 - 0.994, P = 0.045, respectively) At position *Ad rs2241766*, there was a strongly statistical difference observed between the NAFLD patients and their control counterparts (OR: 0.675, 95% CI: 0.481-0.949, P = 0.023; OR: 0.681, 95% CI: 0.485 - 0.956, P = 0.026; OR: 0.730, 95% CI: 0.557 - 0.956, P = 0.022, OR: 0.720, 95% CI: 0.549 - 0.943, P = 0.017, respectively). Nevertheless, there was no statistically significant difference in the *Ad rs2241766* polymorphism between the NAFLD patients with CAD and without CAD (P = 0.965 and 0.921, respectively).

###### Results of the Hardy-Weinberg Equilibrium

  Gene Locus Groups   χ^2^    P
  ------------------- ------- -------
  ***rs266729***              
  CAD+NAFLD           0.314   0.575
  CAD-NAFLD           3.017   0.082
  Controls            3.324   0.068
  ***rs2241766***             
  CAD+NAFLD           0.813   0.367
  CAD-NAFLD           1.829   0.176
  Controls            3.310   0.069

###### Distribution of the Adiponectin *rs266729* and *rs2241766* Polymorphisms in the Study Groups^[a](#fn51933){ref-type="table-fn"}^

  Genotype          CAD+NAFLD    CAD-NAFLD    Controls     OR (95%CI)              χ^2^    P1      OR (95%CI)              χ^2^     P2         OR (95%CI)              χ^2^    P3
  ----------------- ------------ ------------ ------------ ----------------------- ------- ------- ----------------------- -------- ---------- ----------------------- ------- -------
  ***rs266729***                                                                                                                                                               
  CC                127 (51.6)   151 (61.1)   219 (72.0)                                                                                                                       
  GG+GC             119 (48.4)   96 (38.9)    85 (28.0)    0.679 (0.474 - 0.970)   4.530   0.033   0.414 (0.291 - 0.590)   24.283   \< 0.001   0.610 (0.427 - 0.873)   7.348   0.007
  Allele C          351 (71.3)   380 (76.9)   511 (84.0)                                                                                                                       
  Allele G          141 (28.7)   114 (23.1)   97 (16.0)    0.747 (0.561 - 0.994)   4.005   0.045   0.473 (0.353 - 0.633)   25.888   \< 0.001   0.633 (0.468 - 0.855)   8.933   0.003
  ***rs2241766***                                                                                                                                                              
  TT                126 (51.2)   127 (51.4)   185 (60.9)                                                                                                                       
  GG+GT             120 (48.8)   120 (48.6)   119 (39.4)   0.992 (0.697 - 1.412)   0.002   0.965   0.675 (0.481 - 0.949)   5.138    0.023      0.681 (0.485 - 0.956)   4.943   0.026
  Allele T          348 (70.7)   348 (70.4)   467 (76.8)                                                                                                                       
  Allele G          144 (29.3)   146 (29.6)   141 (23.2)   1.014 (0.771 - 1.333)   0.010   0.921   0.730 (0.557 - 0.956)   5.233    0.022      0.720 (0.549 - 0.943)   5.731   0.017

Abbreviations: CAD+NAFLD, nonalcoholic fatty liver disease patients with coronary artery disease; CAD-NAFLD, NAFLD patients without CAD; P1, CAD+NAFLD vs. CAD-NAFLD; P2, CAD+NAFLD vs. control; P3, CAD-NAFLD vs. control.

^a^Values are expressed as mean ± SD.

4.3. Association of the Ad Polymorphisms with Clinical Parameters in NAFLD Patients {#sec186498}
-----------------------------------------------------------------------------------

We compared the *Ad rs266729* and *rs2241766* genotypes with the clinical characteristics of the NAFLD patients, with or without CAD and the control group to estimate whether the *rs266729* and *rs2241766* gene polymorphisms were correlated with clinical parameters ([Table 4](#tbl47203){ref-type="table"}). With regard to position *rs266729*, the serum TG, TC, FPG, and LDL levels of the NAFLD CAD patients with a CG+GG genotype were significantly higher than those with a CC genotype (P = 0.031, P = 0.034, P = 0.007, and P \< 0.001, respectively). With regard to *Ad rs266729* (CG+GG) the genotype of NAFLD patients with CAD showed lower Ad levels in serum than those with the CC genotype (P \< 0.001). Furthermore, CAD-free NAFLD patients with the *rs266729* (CG+GG) genotype exhibited higher TG and serum FPG levels and lower serum Ad levels than those with the CC genotype (P = 0.014, P = 0.038, and P \< 0.001, respectively). In both the NAFLD groups, the serum TG levels of those with the rs2241766 GT+GG genotype were higher than those with the *rs2241766* TT genotype (P = 0.039 and P = 0.042, respectively). No other statistically significant differences were observed between the controls, with regards to the presence of the *rs2241766* gene polymorphism (P \> 0.05).

###### Comparison of Adiponectin *rs266729* and *rs2241766* Genotypes With Clinicopathological Parameters^[a](#fn50310){ref-type="table-fn"}^

  Parameters              *rs266729*      *rs2241766*                                                        
  ----------------------- --------------- -------------------------------------------------- --------------- -------------------------------------------------
  **CAD+NAFLD**           N = 119         N = 127                                            N = 120         N = 126
  Age, y                  46.54 ± 11.04   46.39 ± 12.08                                      46.39 ± 11.21   45.94 ± 11.09
  Gender, Female/Male     57/62           62/65                                              59/61           60/66
  Height, m               1.67 ± 0.06     1.67 ± 0.08                                        1.67 ± 0.07     1.68 ± 0.02
  Weight, kg              67.53 ± 6.31    65.98 ± 7.02                                       68.21 ± 5.98    67.34 ± 6.56
  Smoker, No. (%)         67 (56.30)      61 (48.03)                                         58 (48.3)       63 (50.0)
  BMI, kg/m^2^            24.29 ± 3.76    25.31 ± 3.32                                       23.67 ± 4.62    24.54 ± 3.21
  Hypertension, No. (%)   60 (50.4)       61 (48.0)                                          58 (48.3)       60 (47.6)
  ALT, U/L                44.52 ± 21.43   43.62 ± 22.36                                      44.31 ± 21.54   43.96 ± 21.09
  AST, U/L                41.34 ± 20.31   40.56 ± 21.09                                      40.99 ± 21.23   39.62 ± 20.97
  TG, mmol/L              2.85 ± 1.08     2.21 ± 0.96^[b](#fn50311){ref-type="table-fn"}^    2.83 ± 1.00     2.68 ± 0.96^[c](#fn50312){ref-type="table-fn"}^
  TC, mmol/L              5.62 ± 1.34     5.21 ± 0.99^[d](#fn50313){ref-type="table-fn"}^    5.67 ± 1.02     5.36 ± 1.01
  FPG, mmol/L             5.33 ± 0.73     5.01 ± 0.61^[e](#fn50314){ref-type="table-fn"}^    5.27 ± 0.63     5.17 ± 0.59
  HDL, mmol/L             1.37 ± 0.41     1.34 ± 0.42                                        1.43 ± 0.39     1.41 ± 0.41
  LDL, mmol/L             3.43 ± 0.94     2.96 ± 0.89^[f](#fn50315){ref-type="table-fn"}^    3.29 ± 0.97     3.21 ± 0.71
  Adiponectin, ug/mL      13.62 ± 4.32    16.82 ± 4.47^[g](#fn50316){ref-type="table-fn"}^   13.38 ± 3.21    14.98 ± 3.92
  **CAD-NAFLD**           **N = 96**      **N = 151**                                        **N = 120**     **N = 127**
  Age, y                  62.87 ± 9.65    62.09 ± 9.87                                       62.41 ± 9.51    62.08 ± 9.61
  Gender, Female/Male     49/47           73/78                                              58/62           63/64
  Height, m               1.67 ± 0.06     1.67 ± 0.05                                        1.66 ± 0.08     1.67 ± 0.06
  Weight, kg              66.58 ± 6.71    67.32 ± 7.01                                       66.42 ± 6.52    66.67 ± 6.81
  Smoker, No. (%)         39 (40.6)       65 (43.0)                                          41 (34.2)       46 (36.2)
  BMI, kg/m^2^            24.89 ± 3.62    25.01 ± 3.01                                       24.42 ± 3.31    24.65 ± 3.45
  Hypertension, No (%)    38 (39.6)       60 (39.7)                                          43 (35.8)       47 (37.0)
  ALT, U/L                41.02 ± 21.32   40.61 ± 20.56                                      41.45 ± 20.67   41.21 ± 20.11
  AST, U/L                41.34 ± 22.09   40.21 ± 21.89                                      41.01 ± 21.09   40.56 ± 21.11
  TG, mmol/L              2.23 ± 0.81     2.01 ± 0.75^[h](#fn50317){ref-type="table-fn"}^    2.21 ± 0.76     2.17 ± 0.69^[i](#fn50318){ref-type="table-fn"}^
  TC, mmol/L              5.04 ± 0.91     5.05 ± 0.89                                        5.04 ± 0.84     5.04 ± 0.69
  FPG, mmol/L             5.21 ± 0.61     4.94 ± 0.57^[j](#fn50319){ref-type="table-fn"}^    5.19 ± 0.21     5.16 ± 0.22
  HDL, mmol/L             1.34 ± 0.32     1.36 ± 0.41                                        1.32 ± 0.25     1.35 ± 0.32
  LDL, mmol/L             2.63 ± 0.67     2.61 ± 0.68                                        2.59 ± 0.65     2.61 ± 0.67
  Adiponectin, ug/mL      13.26 ± 4.21    15.56 ± 4.31^[k](#fn50320){ref-type="table-fn"}^   14.26 ± 3.89    15.63 ± 4.01
  **Controls**            **N = 85**      **N = 219**                                        **N = 119**     **N = 185**
  Age, y                  61.09 ± 9.21    61.23 ± 9.31                                       62.21 ± 9.02    61.59 ± 9.11
  Gender, Female/Male     41/44           111/108                                            57/62           95/90
  Height, m               1.68 ± 0.07     1.67 ± 0.09                                        1.68 ± 0.07     1.68 ± 0.08
  Weight, kg              66.65 ± 6.32    67.32 ± 5.94                                       67.01 ± 6.01    67.21 ± 5.45
  Smoker, No. (%)         29 (34.1)       79 (36.1)                                          45 (37.8)       64 (34.6)
  BMI, kg/m^2^            23.11 ± 3.21    22.97 ± 3.01                                       24.01 ± 3.41    23.07 ± 3.01
  Hypertension, No. (%)   31 (36.5)       80 (36.5)                                          37 (31.1)       62 (33.5)
  ALT, U/L                20.31 ± 7.21    20.56 ± 6.91                                       21.21 ± 7.09    20.56 ± 6.18
  AST, U/L                19.71 ± 7.13    20.81 ± 8.07                                       19.76 ± 7.85    19.81 ± 8.02
  TG, mmol/L              1.21 ± 0.41     1.41 ± 0.52                                        1.29 ± 0.33     1.36 ± 0.41
  TC, mmol/L              4.32 ± 0.81     4.02 ± 0.71                                        4.01 ± 0.36     4.28 ± 0.52
  FPG, mmol/L             4.86 ± 0.42     4.93 ± 0.31                                        4.92 ± 0.41     4.94 ± 0.44
  HDL, mmol/L             1.54 ± 0.46     1.55 ± 0.41                                        1.54 ± 0.42     1.54 ± 0.42
  LDL, mmol/L             2.59 ± 0.76     2.61 ± 0.71                                        2.61 ± 0.76     2.60 ± 0.68
  Adiponectin, ug/mL      18.78 ± 3.21    19.02 ± 3.11                                       19.01 ± 2.97    19.36 ± 3.02

^a^Values are expressed as mean ± SD unless otherwise indicated.

^b^P = 0.031.

^c^P = 0.039.

^d^P = 0.034.

^e^P = 0.007.

^f^P \< 0.001.

^g^P \< 0.001.

^h^P = 0.014.

^i^P = 0.042.

^j^P = 0.038.

^k^P \< 0.001.

5. Discussion {#sec186500}
=============

In this study, we correlated the expression of the *Ad rs266729* and *rs2241766* gene polymorphisms with the risk of developing CAD in NAFLD patients for the first time. The main finding of our study was that the *Ad rs266729* G allele and *rs2241766* G allele were significantly associated with the occurrence of NAFLD. In addition, the NAFLD patients in this Northern Han Chinese population who carried the *Ad rs266729* G allele had an increased risk of developing CAD. Future studies are required to determine whether and how this polymorphism modulates Ad expression, as well as the role of the Ad polymorphism in the pathogenesis of CAD in the setting of NAFLD.

The Ad gene, which is expressed primarily in adipose and vascular tissues, encodes the protein Ad ([@A37388R24]). Ad has been shown to have anti-inflammatory effects and antiatherosclerotic properties ([@A37388R25]) and to have important roles in insulin sensitivity ([@A37388R7], [@A37388R8]). Overexpression of Ad may contribute to the development of NAFLD, atherosclerosis, and CAD by affecting the metabolism of major lipids, reducing insulin receptor signaling, and blocking insulin actions ([@A37388R16], [@A37388R26], [@A37388R27]). Hashemi et al. ([@A37388R28]) reported that the prevalence of *Adrs266729* in Iranian patients with NAFLD was higher than that of controls. Similar findings were reported in some Chinese populations ([@A37388R16]). Our results also showed that the frequency of the *Ad rs266729* G allele was higher in the NAFLD groups than in the control group. Moreover, the Ad polymorphism at position *rs266729* G allele increased TG, TC, and LDL levels in patients with NAFLD. These results are consistent with other Chinese data ([@A37388R16]). In addition, the serum Ad level was decreased in those with the G allele and the Ad polymorphism at position *rs266729*. In common with the findings of the preset study, Wang et al. ([@A37388R29]) reported that variant alleles at *rs266729* were associated with lower Ad levels.

Although the results indicate that the G allele of *Ad rs266729* may contribute to the development of NAFLD, there is no consensus on whether *rs2241766* is a risk factor for the prevalence of NAFLD. Tokushige et al. ([@A37388R30]) discovered that the *Ad rs2241766* genotype GG was related to the progression of NAFLD in Japanese patients. However, Wang et al. ([@A37388R31]) revealed that this genotype was not significantly associated with NAFLD in a Southern Han Chinese population. Interestingly, in the current study, we found that *Ad rs2241766* was associated with NAFLD in a Northern Han Chinese population. However, further studies with larger samples and different ethnicities or races are needed to confirm the findings ([@A37388R27]).

CAD is a multifactorial disorder. The results of previous studies on the association between Ad gene polymorphisms and the risk of CAD are conflicting. One study of a Northeast Han Chinese population showed that the presence of the Ad rs2082940 variant was significantly associated with CAD ([@A37388R7]). Specifically, these investigators found that the Ad rs2082940 G allele seemed to protect against the progression of CAD. On the other hand, Tong et al. ([@A37388R17]) found that the presence of the G allele of the *rs266729* was strongly correlated with an increased prevalence of CAD in Europeans. Hoefle et al. ([@A37388R32]) reached the same conclusion in a study of an Australian population. A recent meta-analysis concluded that there was a strong association between *Ad rs266729* and cardiovascular disease ([@A37388R33]). In agreement with previous studies, Foucan et al. ([@A37388R34]) showed that French patients carrying the *Ad rs2241766* G allele had an increased risk of CAD. Other studies have reported discordant findings because of differences in ethnicity, phenotypes, and environments ([@A37388R16], [@A37388R33]). In the present study, the frequency of the *Ad rs266729* G allele in NAFLD patients with CAD was substantially higher than in those without CAD. In addition, NAFLD patients with CAD who carried the *Ad rs266729* G allele had increased serum TG, TC, and LDL levels compared to those who did not carry the G allele. The *Ad rs2241766* polymorphism was not associated with the risk of developing CAD, but it had detrimental effects on lipid levels in NAFLD patients with CAD, indicating that the Ad G allele could lead to insulin resistance in CAD patients and that it may increase the risk of cardiovascular complications. Several previous studies showed that high concentrations of serum Ad decreased the risk of CAD in male diabetic patients ([@A37388R35]), the risk of myocardial infarction in healthy men ([@A37388R36]), and cardiovascular disease outcomes in patients with end-stage renal failure ([@A37388R37]). In addition, Ad increased the production of endothelial NO, which has well-documented antithrombotic, antiatherogenic, and vasodilatory actions ([@A37388R38], [@A37388R39]). Thus, the literature demonstrates that Ad may have potential benefits in the treatment and prevention of cardiovascular disease ([@A37388R40]). Further studies are needed to associate the Ad single-nucleotide polymorphism with expression of the Ad protein.

Some limitations of our study should be acknowledged. First, the entire study population was racially homogeneous, and the participants were all Han. Moreover, the population was highly selected. Therefore, our results may not be applicable to other populations. Second, we used ultrasonography to diagnose NAFLD because of the difficulty in obtaining a liver biopsy. Third, our study did not correlate Ad polymorphisms with the level of expression and insulin resistance or disease severity in NAFLD patients. Finally, larger sample sizes and diverse ethnic groups are needed in future studies to confirm the present data.

In conclusion, we found that the presence of the *Ad rs266729* G allele increased the risk of CAD in NAFLD patients. The *Ad rs2241766* G allele may a risk factor for the development of NAFLD but not CAD in these patients. Additional studies are needed to delineate the mechanisms underlying the potential roles of these Ad gene polymorphisms in the risk of CAD in NAFLD.
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